Sleep in Wilson’s disease: Questionnaire based study

Archana B. Netto, Sanjib Sinha, Arun B. Taly, Samhita Panda, Shivaji Rao
Departments of Neurology and Biostatistics, National Institute of Mental Health and Neuro Sciences, Bangalore, India

Abstract

Objective: We proposed to detect sleep abnormalities in Wilson’s disease (WD) using sleep questionnaires. Materials and Methods: Twenty-five patients (M:F = 18:7; age: 24.4 ± 9.2 years) with WD and 24 controls (all males; age: 33.1 ± 9.7 years) were recruited. They underwent phenotypic/magnetic resonance imaging (MRI) evaluation followed by administration of Pittsburgh Sleep Quality Index (PSQI) and Epworth Sleepiness Scale (ESS) questionnaires. Results: The mean age at presentation and diagnosis was 24.4 ± 9.2 and 17.6 ± 7.5 years, respectively. The duration of illness at diagnosis was 14 ± 21.9 months. On PSQI, 15 patients with WD had abnormal PSQI scores of >5 as compared to 6 patients among the controls. The mean PSQI score was significantly more (P = 0.03) in patients compared to the controls. The PSQI worst scores were noted only in WD. Evaluation with ESS showed that three patients with WD scored >10/24, while two among the controls qualified for excessive daytime sleepiness. Overall, assessment by sleep questionnaires detected abnormality in 16 patients with WD as compared to 8 controls (P = 0.004). Subgroup analysis revealed that patients whose duration of illness was >8 years and who were on decoppering treatment had significantly lesser excessive daytime somnolence. Conclusions: Sleep disturbances were observed more often in WD than in controls. Better designed studies will provide a better understanding.

Key Words

Epworth sleepiness scale, Pittsburgh sleep quality index, sleep, sleep questionnaire, Wilson’s disease

Introduction

Sleep related disorders are recognized in a third of the Western population. Sleep related disorders affect the mood, behavior, work and quality of life and pose several health problems and contribute to morbidity and mortality of the existing medical illness. Their recognition and treatment can help in improving the functional ability of the individual while preventing hypertension, psychological disturbances and accidents. Sleep disorders could occur in almost all the diseases affecting central nervous system, e.g. extrapyramidal disorders, especially, Parkinsonism.[3] These and other studies support the notion that dopamine activity is normally influenced by circadian factors.[2]

Wilson’s disease (WD) affects young patients, manifests with wide spectra of neuropsychiatric and systemic manifestations, requiring lifelong decoppering therapy and often other symptomatic medications that could affect sleep.[3] The imaging and pathological features of WD suggest that there is affection of the critical areas that are involved in sleep regulation.[1] There are a few studies referring to the sleep disorders in WD. Portala et al. (2002), in a study of 26 patients with WD, reported reduced night sleep as one of the 12 most common psychopathologic symptoms.[6] Firneisz et al. (2000) reported hypersomnia and sleep onset REM as the main symptom of WD in a 21-year-old man.[8] In view of paucity of such studies in patients with WD, and moreover, WD could be a model among the extrapyramidal disorders, this study was planned.

The aim was to evaluate the frequency and nature of sleep abnormalities in patients with WD, using two validated questionnaires – Pittsburgh Sleep Quality Index (PSQI), Epworth Sleepiness Scale (ESS) in comparison with controls.

Materials and Methods

The cross-sectional study was carried out from January 2007 to January 2009 on patients diagnosed to have WD in the Department of Neurology at the National Institute of Mental Health and Neurosciences, Bangalore. Twenty-five patients (M:F = 18:7; age at evaluation: 24.4 ± 9.25 years) with confirmed diagnosis of WD were prospectively recruited from the weekly Wilson’s disease clinic and in-patient services of Department of Neurology. Patients known to be suffering from any other medical or surgical condition that can cause sleep disorder and/or on medications (except anti-epileptic drugs) were excluded.
Study design
Participants were explained the nature of study and an informed consent was obtained from all of them. Ethical clearance was obtained from the institute ethics committee. The study consisted of a) part 1: phenotypic assessment and b) part 2: evaluation with screening sleep questionnaires, namely, PSQI and ESS.

Control population
Twenty-five healthy controls (all males, age: 33.1 ± 9.7 years) were recruited for the study. They were either the staff of the institute who were not performing shift duties or healthy relatives of in-patients admitted for acquired neurological disorders. Relatives of patients with WD were excluded.

Drug history
Patients were categorized as drug naïve or on decoppering agents and details of other medications given for the symptomatic treatment of tremor, chorea, dystonia, etc. were also obtained. A patient was considered as drug naïve if he had never received decoppering agents (penicillamine or zinc sulfate).

Study proper
After recruitment into the study, the subjects were administered the standardized PSQI and ESS. One patient could not answer the questionnaire due to severe anarthria and hence was not included for analysis. For ESS, a score of more than 10/24 is considered to denote excessive daytime sleepiness. Since all eight questions were not applicable to all the subjects, the percentage of 10/24 (41.5%) was calculated, and if the total ESS score ratio was more than this, it was considered significant. For PSQI, the seven items are scored from 0 to 3 and a composite score out of 21 is calculated. A cut-off score of 5 was treated as abnormal.

Results
Demography and phenotype
Twenty-five patients of WD with mean age at evaluation of 24.4 ± 9.25 years (range: 14–62 years) were studied. The duration of illness at diagnosis was 14 ± 21.98 months. The mean duration of illness at evaluation, computed from initial neurological symptom suggestive of WD to the time of recruitment into the study, was 121.33 ± 129.33 months (range: 2–312 months). History of consanguineous parentage was noted in 13/25 patients (52%) and a family history suggestive of WD was noted in 10/25 (40%). Two of these were sibs of patients who had died earlier of hepatic disease, strengthening the diagnosis in index cases. Ten patients (40%) had history of jaundice, suggestive of acute hepatitis in the past. Hepatomegaly and splenomegaly were noted in four and five patients, respectively. One patient had undergone splenectomy due to refractory hypersplenism. Two each had joint pain and abdominal swelling. There was no abnormal elevation of liver enzymes or bilirubin in any of the patients at the time of study. Anemia was present in eight patients. The common neurologic abnormalities were the following: tremor 22 (88%), dystarthism 20 (80%), writing difficulty 16 (64%), Parkinsonism 11 (44%), dystonia 12 (48%), ataxia 8 (32%), pyramidal signs 7 (28%), chorea 3 (12%), seizures 6 (24%), and myoclonus 1 (4%), among others. Six patients (24%) had psychiatric manifestations as their dominant symptoms, which included affective disorders – mania (n = 5) and schizophreniform psychosis (n = 1). In addition, mental subnormality was observed in 3 (12%) patients.

Evaluation with sleep questionnaires
Epworth sleepiness scale
Three patients and two controls qualified for excessive daytime sleepiness, and the mean ESS score was not significantly different between the groups (patients: 17.5 ± 15.6; controls: 19.3 ± 13.9; P = 0.66). Subgroup analysis of the patients revealed that individuals with longer duration of illness (abnormal ESS: <8 years, 3; >8 years, 0) and on decoppering treatment (abnormal ESS: drug naïve, 3; on treatment, 19) had significantly lesser “excessive daytime somnolence”. Other variables like gender, young (<20 years) vs. old (≥20 years) age, severity of illness (Chu stage 1 vs. stage 2), and use of anti-epileptic drugs (AEDs) did not influence the scores [Table 1].

Pittsburgh sleep quality index
The seven items of PSQI were scored from 0 to 3 and a

| Table 1: Comparison of the ESS of patients with Wilson’s disease and control subjects |
|----------------------------------|----------------|----------------|----------------|----------------|
| Epworth sleepiness scale         | Would never doze | Slight chance of dozing | Moderate chance of dozing | High chance of dozing |
|                                  | WD  | C   | WD  | C  | WD  | C  | WD  | C  | WD  | C  |
| While sitting and reading*       | 17  | 12  | 4   | 7  | 1   | 1  | 2   |     |     |     |
| Watching TV*                     | 18  | 25  | 1   | 0  | 3   | 0  | 0   |     |     |     |
| Sitting inactive in a public place | 19  | 25  | 4   | 0  | 0   | 1  | 0   |     |     |     |
| As a passenger in a car for an hour without a break | 16  | 16  | 4   | 7  | 2   | 0  | 2   | 2  |     |     |
| Lying down to rest in the afternoon when circumstances permit | 11  | 7   | 1   | 0  | 5   | 5  | 7   | 13 |     |     |
| In a car, while stopped for a few minutes in the traffic* | 15  | 25  | 1   | 0  | 0   | 0  | 0   |     |     |     |
| Sitting and talking to someone   | 23  | 24  | 1   | 0  | 0   | 0  | 1   | 0  |     |     |
| Sitting quietly without alcohol in the afternoon | 9   | 21  | 6   | 1  | 7   | 0  | 2   | 3  |     |     |

*All the questions in the Epworth Sleepiness Scale could not be applied to all the subjects. Q. no. 1 in two cases and three controls; Q. no. 2 in two cases, and Q. no. 6 in eight cases could not be applied ESS score: Patients 17.5 ± 15.6; controls: 19.3 ± 13.9 (P = 0.67), WD, Wilson’s disease, C, control subjects.
composite score out of possible 21 was derived. Fifteen patients had an abnormal PSQI score of $>5$ as compared to six control subjects (chi-square: 8.3; $P = 0.004$). Among the PSQI subscores, six patients had decreased sleep duration of $<6$ hours compared to none among the controls ($P = 0.01$). The mean PSQI score was also significantly more ($P = 0.03$) in patients ($5.5 \pm 3.5$) compared to the controls ($3.5 \pm 2.6$) [Table 2].

**Discussion**

The present study involved patients with WD and healthy controls who were administered ESS and PSQI. These tests were validated against polysomnography. The results revealed 64% ($n = 16$) patients with sleep problems, while they were noted in 32% ($n = 8$) of control subjects. The only other study in literature on sleep abnormalities in patients with WD was by Portala *et al.*, who had used a different sleep inventory, with 24 patients and 72 controls (1:3). Their study detected sleep abnormalities in 42% of patients.[5] Comparison of the sleep abnormalities on a qualitative basis was not possible due to the disparity in questionnaires used. The reason of high prevalence of sleep abnormality in controls is difficult to explain.

WD is an extrapyramidal disorder with both hyperkinetic and hypokinetic manifestations. The present study found that sleep abnormalities varied as much as the clinical features and shared the features with sleep abnormalities in various other extrapyramidal disorders published in literature.[9-11]

The exact reason for sleep disturbances in WD remains to be ascertained. The distribution of neuronal damage by copper deposition and/or encephalopathy due to hepatic dysfunction is highly variable, and may include brainstem nuclei, dentate nucleus, pons, thalamus, basal ganglia, external capsule, claustrum and frontal lobes as well as a certain degree of diffuse brain atrophy.[12,13] The imaging and pathological features of WD suggest that there is affection of the critical areas involved in the regulation of sleep.[14-16] Copper toxicity could be responsible but its role was not substantiated in this study. REM sleep is generated in the brain stem by acetylcholinergic neurons belonging to the cholinergic system (“REM-on” cells). Activation of noradrenergic neurons of locus coeruleus and serotoninergic neurons of dorsal raphe nuclei belonging to the monoaminergic system (“REM-off” cells) inhibits the cholinergic system. Patients with WD may have impairment in the monoaminergic system. An abnormal metabolism of neurotransmitters, probably due to an increase in the activity of copper containing enzymes like dopamine $\beta$-hydroxylase,[15] with increased noradrenaline in the striatum, has been reported.[16,17] Moreover, Nijeholt (1978) reported a decrease both of 5-hydroxyindole acetic acid (5-HIAA, a $\gamma$-HT metabolite) and homovanillic acid (HVA, a metabolite of dopamine) in the lumbar CSF of patients of WD, before and during treatment with penicillamine.[18]

The sample size was small and consisted of a heterogeneous group. A study involving larger number of subjects with more qualitative description of various sleep abnormalities may throw light into the nature of sleep abnormalities in these patients.

**Table 2: Comparison of the PSQI of patients with Wilson's disease (WD) and control subjects**

| Parameters            | WD  | Controls | $P$  |
|-----------------------|-----|----------|------|
| Sleep quality         |     |          |      |
| Good (0, 1)           | 18  | 14       | 0.14 |
| Bad (2, 3)            | 6   | 11       |      |
| Sleep latency         |     |          |      |
| $<30$ min (0, 1)      | 17  | 17       | 0.54 |
| $>30$ min (2, 3)      | 7   | 8        |      |
| Sleep duration        |     |          |      |
| $>6$ hours (0, 1)     | 18  | 25       | 0.01 |
| $<6$ hours (2, 3)     | 6   | 0        |      |
| Sleep efficiency      |     |          |      |
| $>75$ (0, 1)          | 17  | 21       | 0.22 |
| $<75$ (2, 3)          | 7   | 4        |      |
| Sleep disturbance     |     |          |      |
| $<10$ per night (0, 1)| 22  | 22       | 0.52 |
| $>10$ per night (2, 3)| 2   | 3        |      |
| Sleep medications     |     |          |      |
| Never in 1 month (0)  | 24  | 25       | -    |
| Daytime dysfunction   |     |          |      |
| Never in 1 month (0)  | 24  | 25       | -    |
| PSQI score of $>5$    | 15  | 6        | 0.004|
| Mean PSQI score       | 5.4 | 3.5      | 2.6  |

WD, Wilson’s disease, PSQI, Pittsburgh sleep quality index

**References**

1. Gagnon JF, Bodard M, Rantini ML. EM sleep behavior disorder and REM sleep without atonia in Parkinson's disease. Neurology 2002;59:585-9.
2. Rye DB, Jankovic J. Emerging views of dopamine in modulating sleep/wake state from an unlikely source: PD. Neurology 2002:58:341-6.
3. Talty AB, Meenakshi-Sundaram S, Sinha S, Swamy HS, Arunodaya GR. Wilson disease: description of 282 patients evaluated over 3 decades. Medicine (Baltimore) 2007;86:112-21.
4. Sinha S, Talty AB, Ravishankar S, Prasanth LK, Venugopal KS, Arunodaya GR, *et al.* Wilson’s disease: cranial MRI observations and clinical correlation. Neuroradiology 2006;48:613-21.
5. Portala K, Westermark K, Ekselius L, Bromann JE. Sleep in patients with treated Wilson’s disease. A questionnaire study. Nord J Psychiatry 2002;56:291-7.
6. Firmeisz G, Szalay F, Halasz P, Komoly S. Hypersomnia in Wilson’s disease: an unusual symptom in an unusual case. Acta Neurol Scand 2000;101:286-8.
7. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991;14:540-5.
8. Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989;28:193-213.
9. Wetter TC, Collado-Seidel V, Pollmächer T, Yassouridis A, Trenkwalder C. Sleep and periodic leg movement patterns in drug-free patients with Parkinson’s disease and multiple system atrophy. Sleep 2000;23:1-7.
10. Stevens S, Cormella CL, Stepanski EJ. Daytime sleepiness and alertness in patients with Parkinson disease. Sleep 2004;27:967-72.
11. Arnulf I, Merino-Andreau M, Bloch F, Konofal E, Vidalhinet M, Cochen V, *et al.* REM sleep behavior disorder and REM sleep without atonia in patients with progressive supranuclear palsy. Sleep 2005;28:349-54.
12. Schulman S. Wilson's disease. In: Minckler J, editor. Pathology of Nervous System. New York: McGraw-Hill; 1986. p. 1139-51.
13. Scheinberg IH, Sternlieb I. Wilson's disease. In: Smith LH Jr, editor. Major problems in internal medicine. Philadelphia: WB Saunders Company; vol 23, 1984; pp: 1-171.
14. Meenakshi-Sundaram S, Mahadevan A, Taly AB, Arunodaya GR, Swamy HS, Shankar SK. Wilson's disease: a clinico-neuropathological autopsy study. J Clin Neurosci 2008;15:409-17.
15. Barkhatova VP, Larsky G, Markova E, Ivanova-Smolenskaya IA, Demina EG. Changes in concentration of catecholamines in striatum of patients with hepatolenticular degeneration. In: Czlonkowska A, Van den Haner CJ, editors. Proceeding of the 5 Symposium on Wilson’s disease. Delft: Technical University; 1995. p. 165-73.
16. Nyberg P, Gottfries CG, Holmgren G, Persson S, Roos BE, Winblad B. Advanced catecholaminergic disturbances in the brain in a case of Wilson's disease. Acta Neurol Scand 1982;65:71-5.
17. Kish S, Dozik S, Deck J, Shannak K, Hornykiewicz O. Brain adrenergic changes in a patients with Wilson's disease. J Neuropat Exp Neurol 1990;49:280.
18. Nijeholt JL, Korf J. Wilson's disease and monoamines. Arch Neurol 1978;35:617.

Dispatch and return notification by E-mail

The journal now sends email notification to its members on dispatch of a print issue. The notification is sent to those members who have provided their email address to the association/journal office. The email alerts you about an outdated address and return of issue due to incomplete/incorrect address.

If you wish to receive such email notification, please send your email along with the membership number and full mailing address to the editorial office by email.